<DOC>
	<DOCNO>NCT02961504</DOCNO>
	<brief_summary>The primary objective study evaluate efficacy HLCM051 functional outcome subject acute ischemic stroke evaluate safety HLCM051 subject acute ischemic stroke .</brief_summary>
	<brief_title>Treatment Evaluation Acute Stroke Using Regenerative Cell Elements</brief_title>
	<detailed_description>This randomize , placebo-controlled , double-blind , multicenter , phase 2/3 trial evaluate efficacy safety intravenous administration HLCM051 compare placebo subject acute ischemic stroke ( within 36 hour onset ) . Japanese subject develop subcortical ischemic stroke eligible participate trial evaluate . Approximately 220 subject randomize 1:1 ratio ( HLCM051 group [ n=110 ] placebo group [ n=110 ] ) receive single infusion HLCM051 placebo .</detailed_description>
	<mesh_term>Stroke</mesh_term>
	<criteria>Japanese male female patient 20 year age old ; Clinical diagnosis cerebral cortical ischemic stroke ; Occurrence ischemic stroke clear motor speech deficit document National Institutes Health Stroke Scale ( NIHSS ) score 8 20 ( baseline assessment ) change ≥4 point screen baseline assessment ; Onset ischemic stroke must occur within 18 36 hour prior start administration investigational product ; Confirmation hemispheric cortical infarct brain magnetic resonance imaging ( MRI ) include diffusionweighted image bvalue 1,000 demonstrate acute lesion measure ≥ 2.0 cm long diameter ; A modify Rankin Scale ( mRS ) 0 1 , either selfreport family report , prior onset ischemic stroke ; Female patient meet either : Not pregnant , breastfeeding/ interrupt breastfeeding , plan become pregnant trial ; Not childbearing potential , define one postmenopausal least 1 year , surgically sterilize , hysterectomy least 3 month prior start trial ; If childbearing potential , one agree follow investigator 's advice use effective contraceptive method end trial . Effective contraceptive method include contraceptive method use consistently correctly ( oral contraceptive , intrauterine device , diaphragm , male female condom ) , abstinence , sterile sexual partner ; Male patient female partner childbearing potential must agree follow investigator 's advice use adequate contraceptive method ( combination condom another form contraception ) end trial engage sexual intercourse ; Patients legal representative must freely sign informed consent form nature trial disclosure his/her data explain ; Willing able comply aspect treatment test schedule ; Willing able return trial site posttreatment evaluation . Presence lacunar , lesion ≤ 2.0 cm long diameter , brainstem infarct MRI etiology symptom ischemic stroke ; Reduced level consciousness ( score 3 item 1a NIHSS ) ; Occurrence hemorrhagic transformation evidence computerized tomography ( CT ) brain MRI scan clinically significant opinion investigator ; Ipsilateral focal neurological deficit prior lesion brain would complicate evaluation ; Experienced seizures since onset ischemic stroke ; History neurological event stroke clinically significant head trauma within 6 month prior start screen ; Patients receive tPA treatment underwent mechanical reperfusion ( patient eligible trial one , tPA treatment mechanical reperfusion ) ; Uncontrolled hypertension , define persistent systolic blood pressure &gt; 220 mmHg diastolic blood pressure &gt; 120 mmHg , despite antihypertensive therapy ; Blood glucose level &lt; 50 mg/dL &gt; 350 mg/dL baseline ; Patients significant comorbid medical condition ( ) , include , limited : Severe kidney disease require hemodialysis peritoneal dialysis ; Advanced liver disease hepatitis liver cirrhosis ; Severe congestive heart failure history ejection fraction &lt; 30 % ; Severe lung disease require home oxygen ; Active unstable angina require daily treatment nitrate medication ; Known human immunodeficiency virus infection , ongoing systemic infection , severe local infection immunocompromised ; Alzheimer 's disease dementia , Parkinson 's disease , neurological disorder opinion trial doctor would affect ability participate trial confound study assessment ; History malignant tumor ( ) within 2 year onset ischemic stroke , exception adequately treat basal squamous cell carcinoma skin ; Contraindication MRI implant pacemaker metallic prosthesis incompatible MRI , body weight , claustrophobia ; Thrombocytopenia ( platelet count &lt; 100,000/mm3 ) heparininduced thrombocytopenia ; Known allergy human tissue bovine porcine product , religious objection biological product ; Prior participation another clinical trial involve investigational pharmacological agent device within 30 day prior provide consent receive investigational product , participation investigational pharmacological agent , device , rehabilitation stroke recovery program plan trial ; Other serious medical psychiatric illness adequately control , investigator 's opinion , would permit subject manage accord protocol ; Previous surgical removal spleen ; Major fluctuation neurological status since onset ischemic stroke indicate progression expansion ischemic stroke , possible transient ischemic attack ; Plan neurovascular procedure ( e.g. , carotid endarterectomy , stent placement , etc . ) within first year follow ischemic stroke ; Abnormal laboratory test result investigator consider clinically significant inappropriate trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>